Indication
CCND1
3 clinical trials
5 products
1 drug
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCLStatus: Active (not recruiting), Estimated PCD: 2024-07-31
Product
IbrutinibProduct
RituximabClinical trial
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-09-06
Product
BendamustineProduct
ObinutuzumabProduct
VenetoclaxClinical trial
An Open Label, Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)Status: Active (not recruiting), Estimated PCD: 2026-02-08
Drug
Varlilumab